Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.8871
+0.0105 (1.20%)
Apr 24, 2025, 10:29 AM EDT - Market open
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
12.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IMNN News
- 3 days ago - IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study - GlobeNewsWire
- 2 months ago - IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 - GlobeNewsWire
- 2 months ago - IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - GlobeNewsWire
- 2 months ago - IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - IMUNON Appoints Douglas V. Faller, M.D. - GlobeNewsWire